Research programme: Ebola virus vaccine - Pentamer Pharmaceuticals

Drug Profile

Research programme: Ebola virus vaccine - Pentamer Pharmaceuticals

Alternative Names: Ebola DNA vaccine - Pentamer Pharmaceuticals; Ebola peptide vaccine - Pentamer Pharmaceuticals

Latest Information Update: 17 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pentamer Pharmaceuticals
  • Class DNA vaccines; Peptide vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Ebola virus infections

Most Recent Events

  • 16 Oct 2014 Research programme: Ebola virus vaccine - Pentamer Pharmaceuticals is available for licensing as of 16 Oct 2014. http://www.pentamerpharma.com/
  • 14 Oct 2014 Preclinical trials in Ebola virus infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top